Comments on: Immunogen – Another Step towards FDA Approval

By: Ville

Ville — Sat, 28 Aug 2010 10:41:38 +0000

What happened yesterday? Blood bath @ immunogen. Are you still bullish?

By: sam

sam — Sat, 24 Apr 2010 21:24:32 +0000

It will be interesting to read your next writeup on arry because it is one of the few underperformers on your portfolio.

By: Ohad Hammer

Ohad Hammer — Fri, 23 Apr 2010 18:53:38 +0000

Thanks, cloud.

actually the next one is probably gonna be a short piece on ARRY’s recent licensing deal, which is very impressive and unusual imo.

I will try to collect more info on AVEO but I am not sure about timing due to time constraints.

Ohad

By: Cloud

Cloud — Fri, 23 Apr 2010 17:24:29 +0000

Great article Ohad! I look forward to your next one about the IPO AVEO.

Cloud

By: Anik

Anik — Fri, 23 Apr 2010 13:11:23 +0000

Thank you!!!

By: Ohad Hammer

Ohad Hammer — Fri, 23 Apr 2010 12:09:21 +0000

Thanks Anik.
I am not too familiar with them. Regardless of the data they show, the issue I would worry about is off label use.

Ohad

By: Anik

Anik — Thu, 22 Apr 2010 19:13:51 +0000

Hi Ohad,

Thank you for the analysis. you are A PRO.

Are you familiar with PVCT.ob? Phase 2 Data on Provectus’s PV-10 To Be Presented at the 2010 ASCO Scientific Program on June 4 - 8 in Chicago.
Thanks Anik